Reuters logo
BRIEF-Amicus announces top-line phase 3 results for SD-101 in Epidermolysis Bullosa
September 13, 2017 / 10:20 AM / 11 days ago

BRIEF-Amicus announces top-line phase 3 results for SD-101 in Epidermolysis Bullosa

Sept 13 (Reuters) - Amicus Therapeutics Inc

* Amicus Therapeutics announces top-line phase 3 results for SD-101 in Epidermolysis Bullosa

* Study did not meet primary endpoints​

* Phase 3 clinical study did not meet primary endpoints or secondary endpoints in participants with Epidermolysis Bullosa​

* SD-101 did not show a statistically significant difference from placebo in intent to treat (ITT) population​

* Treatment-emergent adverse events (TEAES) were similar across both SD-101 and placebo groups​

* Based on top-line data co has no current plans to invest in additional clinical studies or commercial preparation activities for SD-101​

* Plans to further analyze and share phase 3 essence results with key stakeholders in Epidermolysis Bullosa community​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below